call Toll Free (US/Canada): +1 866 658 6826 | call+1 425 320 4776 | call (UK): +44 1865 60 0662 | call (Ind): +91 9096278110 | email info(@)blueweaveconsulting.com
Home | About Us | Career | Services | Blog | Contact Us
Blueweave
Pulmonary Arterial Hypertension Treatment Market
Inquire Before Buying Request for Sample

Pulmonary Arterial Hypertension Treatment Market

Home Healthcare And Pharmaceutical Pulmonary Arterial Hypertension Treatment Market

Pulmonary Arterial Hypertension (PAH) Treatment Market, By Drug Type (Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Prostacyclin Analogues, Soluble Guanylate Cyclase Stimulators, Others); By Route of Administration (Oral, Intravenous, Subcutaneous, Inhalation); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Region (North America, Europe, Asia Pacific (APAC), Latin America (LATAM), Middle East and Africa (MEA)), Global Trend Analysis, Competitive Landscape & Forecast, 2019–2030

  • Published Date: October 2024
  • Report ID: BWC24793
  • Available Format: PDF
  • Page: 448

Report Overview

An increasing focus on the treatment and management of rising prevalence of pulmonary arterial hypertension (PAH), government support for orphan drug development, technological advancements, favorable reimbursement policies, and growing geriatric population are expected to drive Global Pulmonary Arterial Hypertension (PAH) Treatment Market during the forecast period between 2024 and 2030.

Global Pulmonary Arterial Hypertension (PAH) Treatment Market – Industry Trends & Forecast Report, 2030

Global Pulmonary Arterial Hypertension (PAH) Treatment Market size by value was estimated at USD 7.50 billion in 2023. During the forecast period between 2024 and 2030, Global Pulmonary Arterial Hypertension (PAH) Treatment Market size is expected to expand at a CAGR of 4.80% reaching a value of USD 10.28 billion by 2030. Global Pulmonary Arterial Hypertension (PAH) Treatment Market is driven by several factors. These factors include the rising prevalence of PAH, increasing government support for orphan drug development, and favorable reimbursement policies. Additionally, technological advancements in treatment options, a growing geriatric population, and substantial research and development activities contribute to market expansion. The approval of new drugs and therapies, along with strategic initiatives by key market players, also play significant roles in driving market growth.

Pulmonary Arterial Hypertension Treatment Market

Pulmonary Arterial Hypertension (PAH) Treatment – Overview

Pulmonary arterial hypertension (PAH) treatment focuses on managing symptoms and improving quality of life. It includes supportive therapies like oxygen, diuretics, and anticoagulants, alongside advanced vasodilatory medications targeting pathways such as nitric oxide, endothelin, and prostacyclin. Early intervention is crucial to prevent irreversible changes in pulmonary vasculature. Combination drug therapy is often used to enhance efficacy and reduce morbidity and mortality. Regular exercise and pulmonary rehabilitation are also recommended to improve overall health.

Global Pulmonary Arterial Hypertension (PAH) Treatment Market

Growth Drivers

Increasing Prevalence of Pulmonary Arterial Hypertension (PAH)

The rising prevalence of Global Pulmonary Arterial Hypertension (PAH) (PAH) Treatment Market significantly drives the treatment market. As awareness and diagnostic capabilities improve, more cases are identified, leading to higher demand for effective treatments. This increase is particularly notable in aging populations, where PAH incidence is higher. Enhanced screening programs and a better understanding of PAH's pathophysiology also contribute to the increasing number of patients, necessitating advancements in therapeutic options and fostering market expansion.

Challenges

Lack of Awareness

A significant restraint in Global Pulmonary Arterial Hypertension (PAH) Treatment Market is the lack of awareness in certain regions. Many patients and healthcare providers in developing areas are not well-informed about PAH symptoms, diagnosis, and treatment options. This leads to delayed diagnoses and suboptimal treatment outcomes. Additionally, limited access to specialized healthcare facilities and educational resources further exacerbates the issue, hindering effective management and reducing the overall market growth potential.

Impact of Escalating Geopolitical Tensions on Global Pulmonary Arterial Hypertension (PAH) Treatment Market

Intensifying and further spreading of geopolitical tensions among countries across the major regions could could adversely affect Global Pulmonary Arterial Hypertension (PAH) Treatment Market. Economic, trade, and political tensions often lead to disruptions in the global supply chain, affecting the availability of raw materials and finished products. Trade restrictions and tariffs can increase costs, making treatments less affordable and accessible. Additionally, political instability can divert government focus and funding away from healthcare initiatives, slowing down research and development activities. Pharmaceutical companies may also face challenges in conducting international clinical trials, delaying the approval and launch of new therapies. Overall, geopolitical tensions can hinder market growth by creating an uncertain and unstable environment for both manufacturers and patients.

Global Pulmonary Arterial Hypertension (PAH) Treatment Market

Segmental Coverage

Global Pulmonary Arterial Hypertension (PAH) Treatment Market – By Drug Type

By drug type, Global Pulmonary Arterial Hypertension (PAH) Treatment Market is divided into Endothelin Receptor Antagonists (ERAs), Phosphodiesterase-5 (PDE-5) Inhibitors, Prostacyclin Analogues, Soluble Guanylate Cyclase Stimulators, and Other segments. The endothelin receptor antagonists (ERAs) segment is the largest drug type in Global Pulmonary Arterial Hypertension (PAH) Treatment Market. ERAs dominate the market due to their effectiveness in reducing blood vessel constriction and lowering blood pressure in the lungs. They are widely used as first-line therapy for PAH patients, driving their high adoption. The growing preference for combination therapies, where ERAs are often included, further bolsters this segment's dominance in the market.

Pulmonary Arterial Hypertension Treatment Market Size

Global Pulmonary Arterial Hypertension (PAH) Treatment Market – By Route of Administration

Based on route of administration, Global Pulmonary Arterial Hypertension (PAH) Treatment Market is divided into Oral, Intravenous, Subcutaneous, and Inhalation segments. The oral segment holds the largest market share of Global Pulmonary Arterial Hypertension (PAH) Treatment Market by route of administration. The segment’s dominance is driven by the convenience of oral medications, higher patient compliance, and the availability of effective drugs in oral formulations, such as phosphodiesterase-5 inhibitors and endothelin receptor antagonists. Oral treatments offer a non-invasive alternative to intravenous and subcutaneous methods, making them more accessible and preferable for long-term management of PAH, contributing to their market leadership.

Global Pulmonary Arterial Hypertension (PAH) Treatment Market – By Distribution Channel

By distribution channel, Global Pulmonary Arterial Hypertension (PAH) Treatment Market is divided into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies segments. The hospital pharmacies segment holds the largest share of Global Pulmonary Arterial Hypertension (PAH) Treatment Market by distribution channel. The segment’s dominance is attributed to the higher patient influx in hospitals, where PAH treatments are administered under medical supervision. Hospital pharmacies typically provide specialized medications required for managing PAH, often involving complex therapies that need professional guidance. Additionally, the availability of a broad range of treatments and the trust in hospital-based care further drive the prominence of this segment over others like retail and online pharmacies.

Pulmonary Arterial Hypertension Treatment Market Share

Global Pulmonary Arterial Hypertension (PAH) Treatment Market – By Region

Geographically, Global Pulmonary Arterial Hypertension (PAH) Treatment Market is divided into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), and Middle East and Africa (MEA). North America is the leading region of Global Pulmonary Arterial Hypertension (PAH) Treatment Market. The region’s dominance is driven by the region's advanced healthcare infrastructure, higher awareness of PAH, and greater accessibility to treatment options. Additionally, a higher prevalence of PAH in North America, coupled with strong investments in research and development for new therapies, supports its market leadership. The presence of key pharmaceutical companies further contributes to the region's significant share in Global Pulmonary Arterial Hypertension (PAH) Treatment Market.

Pulmonary Arterial Hypertension Treatment Market Growth

Competitive Landscape

Key players in the highly competitive Global Pulmonary Arterial Hypertension (PAH) Treatment Market include United Therapeutics Ltd, Bayer AG, Actelion Ltd, Pfizer, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Teva Pharmaceuticals Inc., Eli Lilly and Company, Steady Med Ltd, Viatris Inc., Sandoz Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Johnson & Johnson. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

Scope of the Report

Attributes

Details

Years Considered

Historical Data – 2019–2023

Base Year – 2023

Estimated Year – 2024

Forecast Period – 2024–2030

Facts Covered

Revenue in USD Billion 

Market Coverage

North America, Europe, Asia Pacific, Latin America, Middle East and Africa 

Product/Service Segmentation

Drug Type, Route of Administration, Distribution Channel, Region

Key Players

United Therapeutics Ltd, Bayer AG, Actelion Ltd, Pfizer, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Teva Pharmaceuticals Inc., Eli Lilly and Company, Steady Med Ltd, Viatris Inc., Sandoz Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., Johnson & Johnson

 

By Drug Type

  • Endothelin Receptor Antagonists (ERAs)

  • Phosphodiesterase-5 (PDE-5) Inhibitors

  • Prostacyclin Analogues

  • Soluble Guanylate Cyclase Stimulators

  • Others

By Route of Administration

  • Oral

  • Intravenous

  • Subcutaneous

  • Inhalation

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

By Region

  • North America

  • Europe

  • Asia Pacific (APAC)

  • Latin America (LATAM)

  • Middle East and Africa (MEA)

  1. Research Framework
    1. Research Objective
    2. Product Overview
    3. Market Segmentation
  2. Executive Summary
  3. Global Pulmonary Arterial Hypertension Treatment Market Insights
    1. Distribution Channel Value Chain Analysis
    2. DROC Analysis
      1. Growth Drivers
        1. Increasing prevalence of pulmonary arterial hypertension
        2. Advancements in treatment
        3. Rising healthcare spending
      2. Restraints
        1. High cost of treatments
        2. Lack of awareness in some regions
        3. Limited access to specialized care
      3.  Opportunities
        1. Advances in personalized medicine
        2. Development of combination therapies
        3. Increasing demand for digital health solutions
      4. Challenges
        1. Regulatory hurdles for the development and approval of new PAH treatments
        2. Obtaining reimbursement for PAH treatments
    3. Technological Advancements/Recent Developments
    4. Regulatory Framework
    5. Porter’s Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of New Entrants
      4. Threat of Substitutes
      5. Intensity of Rivalry
  4. Global Pulmonary Arterial Hypertension Treatment Market: Marketing Strategies
  5. Global Pulmonary Arterial Hypertension Treatment Market: Pricing Analysis
  6. Global Pulmonary Arterial Hypertension Treatment Market: Geography Analysis
    1. Global Pulmonary Arterial Hypertension Treatment Market, Geographical Analysis, 2023
    2. Global Pulmonary Arterial Hypertension Treatment, Market Attractiveness Analysis, 2024–2030
  7. Global Pulmonary Arterial Hypertension Treatment Market Overview
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Drug Type
        1. Endothelin Receptor Antagonists (ERAs)
        2. Phosphodiesterase–5 (PDE–5) Inhibitors
        3. Prostacyclin Analogues
        4. Soluble Guanylate Cyclase Stimulators
        5. Others
      2. By Route of Administration
        1. Oral
        2. Intravenous
        3. Subcutaneous
        4. Inhalation
      3. By Distribution Channel
        1. Hospital Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies
      4. By Region
        1. North America
        2. Europe
        3. Asia Pacific (APAC)
        4. Latin America (LATAM)
        5. Middle East and Africa (MEA)
  8. North America Pulmonary Arterial Hypertension Treatment Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Drug Type
      2. By Route of Administration
      3. By Distribution Channel
      4. By Country
        1. United States
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        2. Canada
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
  9. Europe Pulmonary Arterial Hypertension Treatment Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Drug Type
      2. By Route of Administration
      3. By Distribution Channel
      4. By Country
        1. Germany
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        2. United Kingdom
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        3. Italy
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        4. France
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        5. Spain
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        6. Belgium
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        7. Russia
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        8. The Netherlands
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        9. Rest of Europe
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
  10. Asia Pacific Pulmonary Arterial Hypertension Treatment Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Drug Type
      2. By Route of Administration
      3. By Distribution Channel
      4. By Country
        1. China
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        2. India
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        3. Japan
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        4. South Korea
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        5. Australia & New Zealand
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        6. Indonesia
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        7. Malaysia
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        8. Singapore
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        9. Vietnam
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        10. Rest of APAC
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
  11. Latin America Pulmonary Arterial Hypertension Treatment Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Drug Type
      2. By Route of Administration
      3. By Distribution Channel
      4. By Country
        1. Brazil
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        2. Mexico
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        3. Argentina
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        4. Peru
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        5. Rest of LATAM
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
  12. Middle East & Africa Pulmonary Arterial Hypertension Treatment Market
    1. Market Size & Forecast, 2019–2030
      1. By Value (USD Billion)
    2. Market Share & Forecast
      1. By Drug Type
      2. By Route of Administration
      3. By Distribution Channel
      4. By Country
        1. Saudi Arabia
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        2. UAE
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        3. Qatar
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        4. Kuwait
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        5. South Africa
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        6. Nigeria
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        7. Algeria
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
        8. Rest of MEA
          1. By Drug Type
          2. By Route of Administration
          3. By Distribution Channel
  13. Competitive Landscape
    1. List of Key Players and Their Offerings
    2. Global Pulmonary Arterial Hypertension Treatment Company Market Share Analysis, 2023
    3. Competitive Benchmarking, By Operating Parameters
    4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)
  14. Impact of Escalating Geopolitical Tensions on Global Pulmonary Arterial Hypertension Treatment Market
  15. Company Profiles (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, and SWOT Analysis)
    1. United Therapeutics Ltd
    2. Bayer AG
    3. Actelion Ltd
    4. Pfizer, Inc.
    5. Gilead Sciences, Inc.
    6. GlaxoSmithKline plc
    7. Teva Pharmaceuticals Inc.
    8. Eli Lilly and Company
    9. Steady Med Ltd
    10. Viatris Inc.
    11. Sandoz Inc.
    12. Lupin Pharmaceuticals, Inc.
    13. Sun Pharmaceutical Industries, Inc.
    14. Johnson & Johnson
    15. Other Prominent Players
  16. Key Strategic Recommendations
  17. Research Methodology
    1.    Qualitative Research
      1.  Primary & Secondary Research
    2.    Quantitative Research
    3.    Market Breakdown & Data Triangulation
      1.  Secondary Research
      2.  Primary Research
    4.    Breakdown of Primary Research Respondents, By Region
    5.    Assumptions & Limitations

*Financial information of non–listed companies can be provided as per availability.

**The segmentation and the companies are subject to modifications based on in–depth secondary research for the final deliverable

 

 

List of Figures

 

Figure 1       Global Pulmonary Arterial Hypertension Treatment Segmentation

Figure 2       Global Pulmonary Arterial Hypertension Treatment Market Value Chain Analysis

Figure 3       Company Market Share Analysis, 2023

Figure 4       Global Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 5       Global Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 6       Global Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 7       Global Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 8       Global Pulmonary Arterial Hypertension Treatment Market Share, By Region, By Value (USD Billion), 2019–2030

Figure 9       North America Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 10     North America Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 11     North America Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 12     North America Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 13     North America Pulmonary Arterial Hypertension Treatment Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 14     United States Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 15     United States Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 16     United States Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 17     United States Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 18     Canada Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 19     Canada Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 20     Canada Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 21     Canada Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 22     Europe Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 23     Europe Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 24     Europe Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 25     Europe Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 26     Europe Pulmonary Arterial Hypertension Treatment Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 27     Germany Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 28     Germany Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 29     Germany Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 30     Germany Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 31     United Kingdom Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 32     United Kingdom Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 33     United Kingdom Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 34     United Kingdom Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 35     Italy Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 36     Italy Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 37     Italy Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 38     Italy Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 39     France Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 40     France Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 41     France Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 42     France Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 43     Spain Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 44     Spain Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 45     Spain Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 46     Spain Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 47     Belgium Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 48     Belgium Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 49     Belgium Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 50     Belgium Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 51     Russia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 52     Russia Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 53     Russia Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 54     Russia Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 55     The Netherlands Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 56     The Netherlands Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 57     The Netherlands Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 58     The Netherlands Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 59     Rest of Europe Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 60     Rest of Europe Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 61     Rest of Europe Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 62     Rest of Europe Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 63     Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 64     Asia Pacific Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 65     Asia Pacific Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 66     Asia Pacific Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 67     Asia Pacific Pulmonary Arterial Hypertension Treatment Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 68     China Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 69     China Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 70     China Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 71     China Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 72     India Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 73     India Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 74     India Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 75     India Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 76     Japan Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 77     Japan Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 78     Japan Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 79     Japan Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 80     South Korea Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 81     South Korea Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 82     South Korea Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 83     South Korea Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 84     Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 85     Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 86     Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 87     Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 88     Indonesia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 89     Indonesia Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 90     Indonesia Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 91     Indonesia Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 92     Malaysia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 93     Malaysia Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 94     Malaysia Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 95     Malaysia Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 96     Singapore Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 97     Singapore Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 98     Singapore Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 99     Singapore Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 100   Vietnam Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 101   Vietnam Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 102   Vietnam Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 103   Vietnam Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 104   Rest of APAC Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 105   Rest of APAC Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 106   Rest of APAC Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 107   Rest of APAC Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 108   Latin America Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 109   Latin America Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 110   Latin America Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 111   Latin America Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 112   Latin America Pulmonary Arterial Hypertension Treatment Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 113   Brazil Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 114   Brazil Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 115   Brazil Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 116   Brazil Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 117   Mexico Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 118   Mexico Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 119   Mexico Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 120   Mexico Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 121   Argentina Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 122   Argentina Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 123   Argentina Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 124   Argentina Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 125   Peru Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 126   Peru Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 127   Peru Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 128   Peru Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 129   Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 130   Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 131   Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 132   Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 133   Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 134   Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 135   Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 136   Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 137   Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Share, By Country, By Value (USD Billion), 2019–2030

Figure 138   Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 139   Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 140   Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 141   Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 142   UAE Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 143   UAE Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 144   UAE Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 145   UAE Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 146   Qatar Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 147   Qatar Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 148   Qatar Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 149   Qatar Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 150   Kuwait Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 151   Kuwait Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 152   Kuwait Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 153   Kuwait Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 154   South Africa Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 155   South Africa Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 156   South Africa Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 157   South Africa Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 158   Nigeria Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 159   Nigeria Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 160   Nigeria Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 161   Nigeria Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 162   Algeria Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 163   Algeria Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 164   Algeria Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 165   Algeria Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

Figure 166   Rest of MEA Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Figure 167   Rest of MEA Pulmonary Arterial Hypertension Treatment Market Share, By Drug Type, By Value (USD Billion), 2019–2030

Figure 168   Rest of MEA Pulmonary Arterial Hypertension Treatment Market Share, By Route of Administration, By Value (USD Billion), 2019–2030

Figure 169   Rest of MEA Pulmonary Arterial Hypertension Treatment Market Share, By Distribution Channel, By Value (USD Billion), 2019–2030

 

List of Tables

 

Table 1        Global Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 2        Global Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 3        Global Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 4        Global Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 5        Global Pulmonary Arterial Hypertension Treatment Market Size, By Region, By Value (USD Billion), 2019–2030

Table 6        North America Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 7        North America Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 8        North America Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 9        North America Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 10      North America Pulmonary Arterial Hypertension Treatment Market Size, By Country, By Value (USD Billion), 2019–2030    

Table 11      United States Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 12      United States Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 13      United States Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 14      United States Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 15      Canada Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 16      Canada Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 17      Canada Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 18      Canada Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 19      Europe Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 20      Europe Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 21      Europe Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 22      Europe Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 23      Europe Pulmonary Arterial Hypertension Treatment Market Size, By Country, By Value (USD Billion), 2019–2030

Table 24      Germany Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 25      Germany Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 26      Germany Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 27      Germany Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 28      United Kingdom Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 29      United Kingdom Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 30      United Kingdom Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 31      United Kingdom Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 32      Italy Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 33      Italy Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 34      Italy Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 35      Italy Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 36      France Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 37      France Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 38      France Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 39      France Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 40      Spain Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 41      Spain Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 42      Spain Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 43      Spain Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 44      Belgium Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 45      Belgium Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 46      Belgium Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 47      Belgium Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 48      Russia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 49      Russia Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 50      Russia Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 51      Russia Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 52      The Netherlands Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 53      The Netherlands Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 54      The Netherlands Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 55      The Netherlands Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 56      Rest of Europe Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 57      Rest of Europe Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 58      Rest of Europe Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 59      Rest of Europe Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 60      Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 61      Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 62      Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 63      Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 64      Asia Pacific Pulmonary Arterial Hypertension Treatment Market Size, By Country, By Value (USD Billion), 2019–2030    

Table 65      China Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 66      China Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 67      China Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 68      China Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 69      India Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 70      India Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 71      India Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 72      India Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 73      Japan Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 74      Japan Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 75      Japan Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 76      Japan Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 77      South Korea Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 78      South Korea Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 79      South Korea Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 80      South Korea Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 81      Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030    

Table 82      Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030 

Table 83      Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030 

Table 84      Australia & New Zealand Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030      

Table 85      Indonesia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 86      Indonesia Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 87      Indonesia Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 88      Indonesia Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 89      Malaysia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 90      Malaysia Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 91      Malaysia Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 92      Malaysia Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 93      Singapore Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 94      Singapore Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 95      Singapore Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 96      Singapore Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 97      Vietnam Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 98      Vietnam Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 99      Vietnam Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 100    Vietnam Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 101    Rest of APAC Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 102    Rest of APAC Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 103    Rest of APAC Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 104    Rest of APAC Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 105    Latin America Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 106    Latin America Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 107    Latin America Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 108    Latin America Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 109    Latin America Pulmonary Arterial Hypertension Treatment Market Size, By Country, By Value (USD Billion), 2019–2030    

Table 110    Brazil Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 111    Brazil Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 112    Brazil Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 113    Brazil Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 114    Mexico Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 115    Mexico Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 116    Mexico Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 117    Mexico Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 118    Argentina Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 119    Argentina Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 120    Argentina Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 121    Argentina Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 122    Peru Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 123    Peru Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 124    Peru Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 125    Peru Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 126    Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 127    Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 128    Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 129    Rest of LATAM Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 130    Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 131    Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030      

Table 132    Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030      

Table 133    Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 134    Middle East and Africa Pulmonary Arterial Hypertension Treatment Market Size, By Country, By Value (USD Billion), 2019–2030

Table 135    Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 136    Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 137    Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 138    Saudi Arabia Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 139    UAE Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 140    UAE Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 141    UAE Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 142    UAE Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 143    Qatar Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 144    Qatar Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 145    Qatar Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 146    Qatar Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 147    Kuwait Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 148    Kuwait Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 149    Kuwait Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 150    Kuwait Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 151    South Africa Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030

Table 152    South Africa Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030     

Table 153    South Africa Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 154    South Africa Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 155    Nigeria Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 156    Nigeria Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 157    Nigeria Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 158    Nigeria Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 159    Algeria Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 160    Algeria Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030

Table 161    Algeria Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 162    Algeria Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030

Table 163    Rest of MEA Pulmonary Arterial Hypertension Treatment Market Size, By Value (USD Billion), 2019–2030        

Table 164    Rest of MEA Pulmonary Arterial Hypertension Treatment Market Size, By Drug Type, By Value (USD Billion), 2019–2030    

Table 165    Rest of MEA Pulmonary Arterial Hypertension Treatment Market Size, By Route of Administration, By Value (USD Billion), 2019–2030

Table 166    Rest of MEA Pulmonary Arterial Hypertension Treatment Market Size, By Distribution Channel, By Value (USD Billion), 2019–2030 

Table 167    United Therapeutics Ltd Company Overview

Table 168    United Therapeutics Ltd Financial Overview

Table 169    Bayer AG Company Overview

Table 170    Bayer AG Financial Overview

Table 171    Actelion Ltd Company Overview

Table 172    Actelion Ltd Financial Overview

Table 173    Pfizer, Inc. Company Overview

Table 174    Pfizer, Inc. Financial Overview

Table 175    Gilead Sciences, Inc. Company Overview

Table 176    Gilead Sciences, Inc. Financial Overview

Table 177    GlaxoSmithKline plc Company Overview

Table 178    GlaxoSmithKline plc Financial Overview

Table 179    Teva Pharmaceuticals Inc. Company Overview

Table 180    Teva Pharmaceuticals Inc. Financial Overview

Table 181    Eli Lilly and Company: Company Overview

Table 182    Eli Lilly and Company Financial Overview

Table 183    Steady Med Ltd Company Overview

Table 184    Steady Med Ltd Financial Overview

Table 185    Viatris Inc. Company Overview

Table 186    Viatris Inc. Financial Overview

Table 187    Sandoz Inc. Company Overview

Table 188    Sandoz Inc. Financial Overview

Table 189    Lupin Pharmaceuticals, Inc. Company Overview

Table 190    Lupin Pharmaceuticals, Inc. Financial Overview

Table 191    Sun Pharmaceutical Industries, Inc. Company Overview

Table 192    Sun Pharmaceutical Industries, Inc. Financial Overview

Table 193    Johnson & Johnson Company Overview

Table 194    Johnson & Johnson Financial Overview

Market Segmentation

No data available
No data available

To request a free sample copy of this report, please complete the form below.

We value your investment and offer free customization with every report to fulfil your exact research needs.

This website is secure and your personal details are safe.

Frequently Asked Questions (FAQs):

Ans: Global Pulmonary Arterial Hypertension (PAH) Treatment Market size by value was estimated at USD 7.50 billion in 2023.
Ans: Global Pulmonary Arterial Hypertension (PAH) Treatment Market by value is expected to grow at a CAGR of 4.80% during the forecast period between 2024 and 2030.
Ans: Global Pulmonary Arterial Hypertension (PAH) Treatment Market size is forecast to reach a value of USD 10.28 billion by 2030.
Ans: Growth of Global Pulmonary Arterial Hypertension (PAH) Treatment Market is primarily driven by the rising prevalence of Pulmonary Arterial Hypertension (PAH), government support for orphan drug development, technological advancements, favorable reimbursement policies, and the increasing geriatric population.
Ans: Key players in Global Pulmonary Arterial Hypertension (PAH) Treatment Market include United Therapeutics Ltd, Bayer AG, Actelion Ltd, Pfizer, Inc., Gilead Sciences, Inc., GlaxoSmithKline plc, Teva Pharmaceuticals Inc., Eli Lilly and Company, Steady Med Ltd, Viatris Inc., Sandoz Inc., Lupin Pharmaceuticals, Inc., Sun Pharmaceutical Industries, Inc., and Johnson & Johnson.
Ans: The oral segment accounts for the highest market share of Global Pulmonary Arterial Hypertension (PAH) Treatment Market by route of administration.